Daflon 500 mg: Symptoms and edema - Clinical update

Angiology

Volumn 56, Issue SUPPL. 1, 2005, Pages

  Ramelet, Albert Adrien ^a  

^a NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DAFLON; DIOSMIN; PLACEBO;

ANKLE; CHRONIC VEIN INSUFFICIENCY; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONSULTATION; DOSE RESPONSE; EDEMA; HUMAN; MUSCLE CRAMP; PAIN; PAIN ASSESSMENT; PARESTHESIA; PRURITUS; QUALITY OF LIFE; SYMPTOMATOLOGY; TECHNIQUE; TREATMENT OUTCOME; VALIDATION PROCESS; VISUAL ANALOG SCALE; ARTICLE; BURN; CYANOSIS; DRUG EFFICACY; DRUG MECHANISM; LEUKOCYTE ACTIVATION; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN REDNESS; SWELLING; SYMPTOM;

EID: 25444474195     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/00033197050560i105     Document Type: Conference Paper

References (27)

1. Eklof B, Rutherford RB, Bergan JJ, et al; American Venous Forum International Ad Hoc Committee for Revision of the CEAP Classification: Revision of the CEAP classification for chronic venous disorders: Consensus statement. J Vasc Surg 40:1248-1252, 2004.
2. Ramelet AA, Monti M: Phlebology: The Guide. Paris: Elsevier, 1999.
3. Kahn SR, M'Ian CE, Lamping DL, et al: Relationship between clinical classification of chronic venous disease and patient-reported quality of life: Results from an international cohort study. J Vasc Surg 39:823-828, 2004.
4. Ruckley CV, Evans CJ, Allan PL, et al: Chronic venous insufficiency: Clinical and duplex correlations. The Edinburgh vein study of venous disorders in general population. J Vasc Surg 36:520-525, 2002.
5. Saharay M, Shields DA, Georgionnos SN, et al: Endothelial activation in patients with chronic venous disease. Eur J Vasc Endovasc Surg 15:342-349, 1998.
6. Saharay M, Shields DA, Porter JV, et al: Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease. J Vasc Surg 26:265-273, 1997.
7. Bauersachs J, Fleming I, Busse R: Pathophysiology of chronic venous insufficiency. Phlebology 11:16-22, 1996.
8. Takase S, Lerond L, Bergan JJ, et al: The inflammatory reaction during venous hypertension in the rat. Microcirculation 7:41-52, 2000.
9. Takase S, Pascarella L, Bergan JJ, et al: Hypertension-induced venous valve remodeling. J Vasc Surg 9:1329-1334, 2004.
10. Danziger N: Pain in peripheral neuropathies: Physiopathology, clinical evaluation and medical management. Rev Neurol 157:1565-1569, 2001.
11. Johnson KO: The roles and functions of cutaneous mechanoreceptors. Curr Opin Neurobiol 11:455-461, 2001.
12. Bouskela E, Cyrino FZGA, Lerond L: Leukocyte adhesion after oxidant challenge in the hamster cheek pouch microcirculation. J Vasc Res 36(suppl 1):11-14, 1999.
13. Shoab SS, Porter J, Scurr JH, et al: Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease-a prospective study. Eur J Vasc Endovasc Surg 17:313-318, 1999.
14. Friesenecker B, Intaglietta M, Tsai AG, et al: Oral administration of purified micronized flavonoid fraction suppresses leukocyte adhesion in ischemia-reperfusion injury: In vivo observations in the hamster skin fold. Int J Microcirc 14:50-55, 1994.
15. Korthuis RJ, Gute D: Adhesion molecule expression in postischemic microvascular dysfunction: Activity of a micronized purified flavonoid fraction. J Vasc Res 36(suppl 1):15-23, 1999.
16. Danielson G, Jungbeck C, Peterson K, et al: A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovasc Surg 3:73-76, 2002.
17. Takase S, Pascarella L, Lerond L, et al: Venous hypertension, inflammation and valve remodeling. Eur J Vasc Endovasc Surg 28:484-493, 2004.
18. Chassignolle JF, Amiel M, Lanfranchi G, et al: Activité thérapeutique de Daflon 500 mg dans l'insuffisance veineuse fonctionnelle. JIM 99(suppl):32-35, 1987.
19. Gilly R, Pillion G, Frileux C: Evaluation of a new vasoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: A double-blind, placebo-controlled study. Phlebology 9:67-70, 1994.
20. Jantet G and the RELIEF Study Group: RELIEF study: First consolidated European data. Angiology 51:31-37, 2000.
21. Jantet G and the RELIEF Study Group: Chronic venous insufficiency- worldwide results of the RELIEF study. Angiology 53:245-256, 2002.
22. Launois R: Construction and validation of quality of life questionnaire in chronic lower limb venous insufficiency (CIVIQ). Qual Life Res 5:539-554, 1996.
23. Coleridge-Smith P, Lok C, Ramelet AA: Venous leg ulcer: A meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 30:198-208, 2005.
24. Ramelet AA: Meta-analysis of clinical trials carried out with Daflon 500 mg in patients with leg ulcers of venous origin. Study report 2005.
25. Cospite M, Dominici A: Advantage of micronisation of Daflon 500 mg compared with a simple diosmine in the treatment of venous insufficiency. Double blind study. Phlébologie 51:243-247, 1998.
26. Berard A, Kurz X, Zuccarelli F, et al: Reliability study of the Leg-O-Meter, an improved tape measure device, in patients with chronic venous insufficiency of the leg. Veines group. Angiology 49:169-173, 1998.
27. Blume J, Langenbahn H, De Champvallins M: Quantification of oedema using the volometer technique: Therapeutic application of Daflon 500 mg in chronic venous insufficiency. Phlebology 7(suppl 2):37-40, 1992.